Base: Rat Intravenous LD50: 10 mg/kg; Mouse Intravenous LD50: 14 mg/kg.
Hydrochloride salt: Rat Oral LD50: 215 mg/kg; Rat Intravenous LD50: 40 mg/kg
Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Hydrocodone | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Magnesium sulfate | The therapeutic efficacy of Ketobemidone can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Ketobemidone may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Orphenadrine | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Pramipexole | Ketobemidone may increase the sedative activities of Pramipexole. |
| Ropinirole | Ketobemidone may increase the sedative activities of Ropinirole. |
| Rotigotine | Ketobemidone may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Ketobemidone. |
| Sodium oxybate | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Thalidomide | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Alvimopan | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Alvimopan. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Ketobemidone is combined with Desmopressin. |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Ketobemidone. |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Ketobemidone. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketobemidone. |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Ketobemidone. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketobemidone. |
| Naltrexone | The therapeutic efficacy of Ketobemidone can be decreased when used in combination with Naltrexone. |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone. |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Ketobemidone. |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketobemidone. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketobemidone. |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Ketobemidone. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Ketobemidone. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketobemidone. |
| Diamorphine | The risk or severity of adverse effects can be increased when Diamorphine is combined with Ketobemidone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Bezitramide is combined with Ketobemidone. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketobemidone. |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Ketobemidone. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketobemidone. |
| Desomorphine | The risk or severity of adverse effects can be increased when Desomorphine is combined with Ketobemidone. |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Ketobemidone. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketobemidone. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ketobemidone. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Ketobemidone is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Nicomorphine. |
| Meptazinol | The therapeutic efficacy of Ketobemidone can be decreased when used in combination with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Carfentanil, C-11. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Ketobemidone. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Benzhydrocodone. |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Ketobemidone. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Ketobemidone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Ketobemidone is combined with Naloxegol. |
| Pegvisomant | The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone. |
| Succinylcholine | The risk or severity of bradycardia can be increased when Succinylcholine is combined with Ketobemidone. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Ketobemidone. |
| Mifepristone | The serum concentration of Ketobemidone can be increased when it is combined with Mifepristone. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Ketobemidone. |
| Mirtazapine | Ketobemidone may increase the serotonergic activities of Mirtazapine. |
| Fluvoxamine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Fluvoxamine. |
| Citalopram | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Citalopram. |
| Duloxetine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Duloxetine. |
| Paroxetine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Paroxetine. |
| Sibutramine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Sibutramine. |
| Zimelidine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Zimelidine. |
| Dapoxetine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Dapoxetine. |
| Milnacipran | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Ketobemidone. |
| Seproxetine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Levomilnacipran. |
| Indalpine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Indalpine. |
| Ritanserin | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Ritanserin. |
| Alaproclate | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Alaproclate. |
| Sertraline | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Sertraline. |
| Ethanol | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone. |
| Phentermine | Phentermine may increase the analgesic activities of Ketobemidone. |
| Pseudoephedrine | Pseudoephedrine may increase the analgesic activities of Ketobemidone. |
| Benzphetamine | Benzphetamine may increase the analgesic activities of Ketobemidone. |
| Diethylpropion | Diethylpropion may increase the analgesic activities of Ketobemidone. |
| Lisdexamfetamine | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Lisdexamfetamine. |
| Mephentermine | Mephentermine may increase the analgesic activities of Ketobemidone. |
| MMDA | MMDA may increase the analgesic activities of Ketobemidone. |
| Midomafetamine | Midomafetamine may increase the analgesic activities of Ketobemidone. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Ketobemidone. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ketobemidone. |